title: Survey of pre-inflammation cytokines levels in radiotherapy-induced-mucositis.
abstract: Mucositis is a toxic side effect of anti-cancer treatments and is a major focus in cancer research. Pro-inflammatory cytokines have previously been implicated in the pathophysiology of chemotherapy-induced mucositis. The aim of this study was to detect a correlation between serum cytokine levels in head and neck (H and N) cancer patients receiving combined chemo-radiation therapy. Thirty patients with H and N epithelial cancer were recruited to this study. All patients received radiotherapy to the H and N region with doses ranging from 50-70 Gray (Gy). Chemotherapy with cisplatin, carboplatin, 5-fluorouracil and taxanes was given to high-risk patients, using standard chemotherapy protocols. Patients were evaluated for mucositis according to WHO common toxicity criteria and blood samples were drawn for inflammatory (IL-1 and TNF-a) and before and during treatment. The mucositis evaluation demonstrated mucositis grade IV in 33.3% of the patients after the 3rd treatment week. At the end of treatment, the number of patients with grade IV mucositis was less. IL-1 and TNF-alpha did not show any correlation with PEG tube installation. The level of cytokines measured before and during therapy showed decreased TNF-alpha especially after the third week of therapy. No relationship between IL-1 and TNF-alpha, level and mucositis grade was shown.
authors.affiliation: Department of Radiotherapy, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Farshad
authors.initials: F
authors.lastname: Seyyednejad
authors.forename: Amirreza
authors.initials: A
authors.lastname: Rezaee
authors.forename: Sarvar
authors.initials: S
authors.lastname: Haghi
authors.forename: Mohamad
authors.initials: M
authors.lastname: Goldust
mesh_terms: D015415:Biomarkers / Q000097:blood; D059248:Chemoradiotherapy / Q000009:adverse effects*; D016207:Cytokines / Q000097:blood*; D006258:Head and Neck Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007375:Interleukin-1 / Q000097:blood; D052016:Mucositis / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000276:immunology*; D020360:Neoadjuvant Therapy / Q000009:adverse effects*; D011832:Radiation Injuries / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000276:immunology*; D011879:Radiotherapy Dosage; D012720:Severity of Illness Index; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D015415:Biomarkers; D016207:Cytokines; D018836:Inflammation Mediators; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha